SPYRE THERAPEUTICS, INC. (SYRE) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 45.70M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -201.34M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $45.70M | $-201.34M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | $41.56M | $-201.64M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $0.00 | $37.61M | $-209.56M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | (m) | $37.02M | $-213.64M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | $40.55M | $-212.15M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | $39.86M | $-214.36M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $0.00 | $44.83M | $-208.57M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $0.00 | $52.89M | $-193.23M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $0.00 | $44.57M | $-156.17M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $688.00K | $37.80M | $-271.27M | (m) | (m) | 5494.33% | (m) | (m) |
| 2023-12-31 | (m) | $886.00K | $25.68M | $-242.30M | (m) | (m) | 2897.86% | (m) | (m) |
| 2023-09-30 | (m) | $1.05M | $9.83M | $-215.55M | (m) | (m) | 932.83% | (m) | (m) |
| 2023-06-30 | (m) | $1.23M | $6.61M | $-215.97M | (m) | (m) | 538.52% | (m) | (m) |
| 2023-03-31 | $55.38M | $1.17M | $6.72M | $-79.15M | (m) | 4753.39% | 576.74% | (m) | (m) |
| 2022-12-31 | $58.58M | $2.33M | $7.11M | $-84.78M | (m) | 2515.20% | 305.32% | (m) | (m) |
| 2022-09-30 | $61.11M | $5.80M | $7.78M | $-86.06M | (m) | 1052.71% | 133.99% | (m) | (m) |
| 2022-06-30 | $63.99M | $7.03M | $8.32M | $-87.60M | (m) | 910.18% | 118.34% | (m) | (m) |
| 2022-03-31 | $62.19M | $20.10M | $8.38M | $-71.88M | (m) | 309.40% | 41.70% | (m) | (m) |
| 2021-12-31 | $57.07M | $18.74M | $8.04M | $-65.65M | (m) | 304.55% | 42.89% | (m) | (m) |
| 2021-09-30 | $56.04M | (m) | $7.56M | $-67.98M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $53.64M | (m) | $7.14M | $-65.81M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $56.93M | (m) | $6.67M | $-80.67M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $59.64M | $0.00 | $6.26M | $-81.48M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $61.45M | (m) | $5.83M | $-80.61M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $66.84M | (m) | $5.50M | $-84.64M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $64.77M | (m) | $5.14M | $-81.70M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $64.60M | $0.00 | $4.88M | $-80.33M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $58.83M | $0.00 | $5.07M | $-73.73M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $49.92M | $0.00 | $4.78M | $-63.83M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $44.24M | $2.38M | $4.53M | $-54.88M | (m) | 1860.30% | 190.33% | (m) | (m) |
| 2018-12-31 | $36.72M | $3.89M | $4.28M | $-45.46M | (m) | 944.42% | 110.08% | (m) | (m) |
| 2018-09-30 | $30.71M | (m) | $3.60M | $-36.78M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $28.02M | (m) | $3.26M | $-32.54M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $24.74M | (m) | $2.93M | $-29.59M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $22.82M | (m) | $2.49M | $-27.68M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $21.77M | (m) | $2.05M | $-26.59M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $20.91M | (m) | $1.76M | $-24.89M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $19.50M | (m) | $1.48M | $-23.67M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $18.14M | (m) | $1.22M | $-21.91M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $11.45M | (m) | $767.00K | $-11.31M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $6.83M | (m) | $147.00K | $-8.90M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |